DMBT1L1

Across TCGA pan-cancer cohorts, DMBT1L1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DMBT1L1 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher DMBT1L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DMBT1L1 expression acts as an unfavorable survival marker.

CESC, THYM, and SARC are the cancer types where DMBT1L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
THYM	OS	Median	All	0.039	0.928	<.001	24	view →
SARC	DFS	Median	All	0.037	0.632	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DMBT1L1–CESC (DFS)

Open the CESC breakdown →